A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam
NCT07444476 · SOLAR Phase 3Recruiting
- Lead sponsor
- Biogen (Industry)
- Enrollment
- 90 (estimated)
- Start date
- 8 Sep 2026
- Primary completion
- 23 Jun 2028 (estimated)
- Study completion
- 22 Jun 2032
- Last update posted
- 2 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Parallel
- Masking
- None
- Arms
- 2
Interventions
- Salanersen Drug
Conditions and primary outcome
- Spinal Muscular Atrophy
Primary outcome
Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Total Score in Treatment-Naïve Cohort (At Month 12)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07444476.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07444476 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.